Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Stroke. 2014 Aug 19;45(10):3048–3054. doi: 10.1161/STROKEAHA.114.006092

Figure 2.

Figure 2

FSTL1 decreased infarct ratio and improved neurological function 24 hours after MCAO. (A) Representative TTC staining images of coronal sections. (B) Quantified Infarct ratio and (C) neurological scores showed that high dosage of FSTL1 decreases infarction and neurological deficits 24 hours after MCAO. * p<0.05 vs. Sham, & p<0.05 vs. MCAO, n=6 for each group.